PubMed® comprises more than 35 million citations for biomedical literature from MEDLINE, life science journals, and online books.

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. 
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. 
Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. PMID: 36764316 Clinical Trial.

A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates. 
Di Tanna GL, Angell B, Urbich M, Lindgren P, Gaziano TA, Globe G, Stollenwerk B. 
Pharmacoeconomics. 2022 Nov;40(11):1095-1105. doi: 10.1007/s40273-022-01174-2. Epub 2022 Aug 12. PMID: 35960435 

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada. 
Goeree R, Burke N, Jobin M, Brown JP, Lawrence D, Stollenwerk B, Willems D, Johnson B. 
Arch Osteoporos. 2022 Apr 26;17(1):71. doi: 10.1007/s11657-022-01106-9. PMID: 35471711 Free PMC article. 

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan. 
Johnson B, Lai EC, Ou HT, Li H, Stollenwerk B. 
Arch Osteoporos. 2021 Oct 12;16(1):155. doi: 10.1007/s11657-021-01020-6. PMID: 34636982 Free PMC article. 

Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. 
Hagino H, Tanaka K, Silverman S, McClung M, Gandra SR, Charokopou M, Adachi K, Johnson B, Stollenwerk B. 
Osteoporos Int. 2021 Oct;32(10):2011-2021. doi: 10.1007/s00198-021-05927-1. Epub 2021 Mar 27. PMID: 33772328

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. 
Söreskog E, Borgström F, Lindberg I, Ström O, Willems D, Libanati C, Kanis JA, Stollenwerk B, Charokopou M. 
Osteoporos Int. 2021 Jul;32(7):1301-1311. doi: 10.1007/s00198-020-05765-7. Epub 2021 Jan 7. PMID: 33411005 Free PMC article. 

Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. 
Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B. 
Osteoporos Int. 2019 Sep;30(9):1745-1754. doi: 10.1007/s00198-019-05064-w. Epub 2019 Jul 3. PMID: 31270592

Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer. 
Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K. 
Eur J Health Econ. 2019 Jul;20(5):739-750. doi: 10.1007/s10198-019-01038-1. Epub 2019 Feb 21. PMID: 30790097

Costs and effects of intra-operative fluorescence molecular imaging - A model-based, early assessment. 
Präger M, Kiechle M, Stollenwerk B, Hinzen C, Glatz J, Vogl M, Leidl R. 
PLoS One. 2018 Jun 1;13(6):e0198137. doi: 10.1371/journal.pone.0198137. eCollection 2018. PMID: 29856875 Free PMC article. 

Longterm persistence and nonrecurrence of depression treatment in Germany: a four-year retrospective follow-up using linked claims data. 
Wagner CJ, Dintsios CM, Metzger FG, L'Hoest H, Marschall U, Stollenwerk B, Stock S. 
Int J Methods Psychiatr Res. 2018 Jun;27(2):e1607. doi: 10.1002/mpr.1607. Epub 2018 Feb 15. PMID: 29446186 Free PMC article. 

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. 
Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. 
Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2. PMID: 29392552 Clinical Trial. 

Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. 
Stollenwerk B, Iannazzo S, Cooper K, Belozeroff V. J 
Med Econ. 2017 Oct;20(10):1110-1115. doi: 10.1080/13696998.2017.1360309. Epub 2017 Aug 14. PMID: 28803497 Free article. 

A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture. 
O'Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, Caloyeras JP, Crittenden DB, Barron R. 
Clin Ther. 2017 Jul;39(7):1276-1290. doi: 10.1016/j.clinthera.2017.05.348. Epub 2017 Jun 17. PMID: 28629610 Free article. 

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. 
Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S. 
Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5. PMID: 28382503

Depression-related treatment and costs in Germany: Do they change with comorbidity? A claims data analysis. 
Wagner CJ, Metzger FG, Sievers C, Marschall U, L'hoest H, Stollenwerk B, Stock S. 
J Affect Disord. 2016 Mar 15;193:257-66. doi: 10.1016/j.jad.2015.12.068. Epub 2016 Jan 2. PMID: 26773923 

Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework. 
Müller D, Gerber-Grote A, Stollenwerk B, Stock S, Auweiler PW, Frey S, Adarkwah CC, de Kinderen R, Hellmich M. 
Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):619-627. doi: 10.1586/14737167.2016.1115721. Epub 2015 Dec 17. PMID: 26548753 

The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. 
Butzke B, Oduncu FS, Severin F, Pfeufer A, Heinemann V, Giessen-Jung C, Stollenwerk B, Rogowski WH. 
Acta Oncol. 2016;55(3):318-28. doi: 10.3109/0284186X.2015.1053983. Epub 2015 Jun 22. PMID: 26098842 

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. 
Schremser K, Rogowski WH, Adler-Reichel S, Tufman AL, Huber RM, Stollenwerk B. 
Pharmacoeconomics. 2015 Nov;33(11):1215-28. doi: 10.1007/s40273-015-0305-8. PMID: 26081300 

Effects of a 3-year nurse-based case management in aged patients with acute myocardial infarction on rehospitalisation, mortality, risk factors, physical functioning and mental health. a secondary analysis of the randomized controlled KORINNA study. 
Kirchberger I, Hunger M, Stollenwerk B, Seidl H, Burkhardt K, Kuch B, Meisinger C, Holle R. 
PLoS One. 2015 Mar 26;10(3):e0116693. doi: 10.1371/journal.pone.0116693. eCollection 2015. PMID: 25811486 Free PMC article. Clinical Trial. 

The excess health care costs of KardioPro, an integrated care program for coronary heart disease prevention. 
Becker C, Holle R, Stollenwerk B. 
Health Policy. 2015 Jun;119(6):778-86. doi: 10.1016/j.healthpol.2015.01.012. Epub 2015 Jan 24. PMID: 25656962 

Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach. 
Stollenwerk B, Welchowski T, Vogl M, Stock S. 
Eur J Health Econ. 2016 Apr;17(3):235-44. doi: 10.1007/s10198-015-0667-z. Epub 2015 Feb 4. PMID: 25648977 

Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model. 
Stollenwerk B, Bartmus T, Klug F, Stock S, Müller D. 
Osteoporos Int. 2015 Apr;26(4):1367-79. doi: 10.1007/s00198-014-3008-7. Epub 2015 Jan 9. PMID: 25572047 

Economic evaluation of genetic screening for Lynch syndrome in Germany. 
Severin F, Stollenwerk B, Holinski-Feder E, Meyer E, Heinemann V, Giessen-Jung C, Rogowski W. 
Genet Med. 2015 Oct;17(10):765-73. doi: 10.1038/gim.2014.190. Epub 2015 Jan 8. PMID: 25569434 Free article. 

The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data. 
Witt S, Leidl R, Becker C, Holle R, Block M, Brachmann J, Silber S, Stollenwerk B. 
PLoS One. 2014 Dec 8;9(12):e114720. doi: 10.1371/journal.pone.0114720. eCollection 2014. PMID: 25486421 Free PMC article. 

Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. 
Mensch A, Stock S, Stollenwerk B, Müller D. 
Pharmacoeconomics. 2015 Mar;33(3):271-83. doi: 10.1007/s40273-014-0236-9. PMID: 25404426 

Cost-Effectiveness Analysis of Ugt1a1 Genotyping Before Colorectal Cancer Treatment with Irinotecan. 
Butzke B, Oduncu F, Heinemann V, Pfeufer A, Giessen C, Stollenwerk B, Rogowski W. 
Value Health. 2014 Nov;17(7):A643. doi: 10.1016/j.jval.2014.08.2326. Epub 2014 Oct 26. PMID: 27202308 Free article. No abstract available. 

Prioritization of Future Outcomes Research Studies in Chronic Myeloid Leukemia: Value of Information Analysis. 
Rochau U, Kühne F, Jahn B, Kurzthaler C, Corro RI, Chhatwal J, Stollenwerk B, Goldhaber-Fiebert JD, Siebert U. 
Value Health. 2014 Nov;17(7):A639. doi: 10.1016/j.jval.2014.08.2301. Epub 2014 Oct 26. PMID: 27202284 Free article. No abstract available. 

Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data. 
Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, Brachmann J, Silber S, Bestehorn K, Stollenwerk B. 
BMC Health Serv Res. 2014 Jun 17;14:263. doi: 10.1186/1472-6963-14-263. PMID: 24938674 Free PMC article. 

Cost effectiveness of external hip protectors in the hospital setting: a modeling study. 
Stollenwerk B, Waldeyer R, Klein-Meding C, Müller D, Stock S. 
Nurs Econ. 2014 Mar-Apr;32(2):89-98. PMID: 24834633 

Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes. 
Müller D, Borsi L, Stracke C, Stock S, Stollenwerk B. 
Eur J Health Econ. 2015 Jun;16(5):517-27. doi: 10.1007/s10198-014-0605-5. Epub 2014 May 13. PMID: 24818587 

The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. 
Koerber F, Waidelich R, Stollenwerk B, Rogowski W. 
BMC Health Serv Res. 2014 Apr 10;14:163. doi: 10.1186/1472-6963-14-163. PMID: 24721557 Free PMC article. 

Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. 
Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, Danner M, Gerber-Grote A. 
Health Econ. 2015 Apr;24(4):481-90. doi: 10.1002/hec.3041. Epub 2014 Mar 4. PMID: 24590819 Free PMC article. 

A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention. 
Hatz MH, Leidl R, Yates NA, Stollenwerk B. 
Pharmacoeconomics. 2014 Apr;32(4):377-93. doi: 10.1007/s40273-013-0128-4. PMID: 24504849 Review. 

Effects of a nurse-based case management compared to usual care among aged patients with myocardial infarction: results from the randomized controlled KORINNA study. 
Meisinger C, Stollenwerk B, Kirchberger I, Seidl H, Wende R, Kuch B, Holle R. 
BMC Geriatr. 2013 Oct 29;13:115. doi: 10.1186/1471-2318-13-115. PMID: 24168465 Free PMC article. Clinical Trial. 

Link between process and appraisal in coverage decisions: an analysis with structural equation modeling. 
Fischer KE, Stollenwerk B, Rogowski WH. 
Med Decis Making. 2013 Nov;33(8):1009-25. doi: 10.1177/0272989X13490837. Epub 2013 Jun 14. PMID: 23771882 

Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. 
Fischer KE, Rogowski WH, Leidl R, Stollenwerk B. 
Health Policy. 2013 Oct;112(3):187-96. doi: 10.1016/j.healthpol.2013.04.011. Epub 2013 May 10. PMID: 23664301 

The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles. 
Liu Y, Dalal K, Stollenwerk B. 
PLoS One. 2013 Apr 18;8(4):e61718. doi: 10.1371/journal.pone.0061718. Print 2013. PMID: 23637891 Free PMC article.

Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. 
Stollenwerk B, Gandjour A, Lüngen M, Siebert U. 
Eur J Health Econ. 2013 Dec;14(6):1035-48. doi: 10.1007/s10198-012-0454-z. Epub 2012 Dec 30. PMID: 23275043 

Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data. 
Gruber EV, Stock S, Stollenwerk B. 
PLoS One. 2012;7(12):e51312. doi: 10.1371/journal.pone.0051312. Epub 2012 Dec 10. PMID: 23251495 Free PMC article. 

Limited economic evidence of carotid artery stenosis diagnosis and treatment: a systematic review. 
Shenoy AU, Aljutaili M, Stollenwerk B. 
Eur J Vasc Endovasc Surg. 2012 Nov;44(5):505-13. doi: 10.1016/j.ejvs.2012.08.010. Epub 2012 Sep 18. PMID: 22995752 Free article. Review. 

A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. 
Zindel S, Stock S, Müller D, Stollenwerk B. 
BMC Health Serv Res. 2012 Jul 9;12:192. doi: 10.1186/1472-6963-12-192. PMID: 22776616 Free PMC article. 

Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. 
Hunger M, Sabariego C, Stollenwerk B, Cieza A, Leidl R. 
Qual Life Res. 2012 Sep;21(7):1205-16. doi: 10.1007/s11136-011-0024-3. Epub 2011 Oct 5. PMID: 21971874 

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. 
Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. 
Oncologist. 2010;15(11):1179-91. doi: 10.1634/theoncologist.2009-0155. Epub 2010 Nov 2. PMID: 21045188 Free PMC article. 

C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. 
Grander W, Dünser M, Stollenwerk B, Siebert U, Dengg C, Koller B, Eller P, Tilg H. 
Chest. 2010 Oct;138(4):856-62. doi: 10.1378/chest.09-1677. Epub 2010 Feb 19. PMID: 20173056 

Financial incentives in the German Statutory Health Insurance: new findings, new questions. 
Stock S, Schmidt H, Büscher G, Gerber A, Drabik A, Graf C, Lüngen M, Stollenwerk B. 
Health Policy. 2010 Jun;96(1):51-6. doi: 10.1016/j.healthpol.2009.12.015. Epub 2010 Jan 27. PMID: 20106543 

Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. 
Schnell-Inderst P, Schwarzer R, Göhler A, Grandi N, Grabein K, Stollenwerk B, Manne J, Klauss V, Siebert U, Wasem J. 
Int J Technol Assess Health Care. 2010 Jan;26(1):30-9. doi: 10.1017/S0266462309990870. PMID: 20059778

[Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]. 
Schwarzer R, Schnell-Inderst P, Grabein K, Göhler A, Stollenwerk B, Grandi N, Klauss V, Wasem J, Siebert U. 
Z Evid Fortbild Qual Gesundhwes. 2009;103(6):319-29. doi: 10.1016/j.zefq.2009.05.020. PMID: 19839204 Review. German. 

Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods. 
Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R. 
Med Decis Making. 2010 May-Jun;30(3):304-13. doi: 10.1177/0272989X09347015. Epub 2009 Oct 8. PMID: 19815659 

The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins. 
Stollenwerk B, Gerber A, Lauterbach KW, Siebert U. 
Med Decis Making. 2009 Sep-Oct;29(5):619-33. doi: 10.1177/0272989X09331810. Epub 2009 Sep 22. PMID: 19773581 

Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events. 
Schnell-Inderst P, Schwarzer R, Göhler A, Grandi N, Grabein K, Stollenwerk B, Klauß V, Wasem J, Siebert U. 
GMS Health Technol Assess. 2009 May 12;5:Doc06. doi: 10.3205/hta000068. PMID: 21289893 Free PMC article. 

Progression-free survival as a surrogate endpoint in advanced breast cancer. 
Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Siebert U. 
Int J Technol Assess Health Care. 2008 Fall;24(4):371-83. doi: 10.1017/S0266462308080495. PMID: 18828930 Free PMC article. 

Preliminary analysis of short-term financial implications of a prevention bonus program: first results from the German Statutory Health Insurance. 
Stock S, Stollenwerk B, Klever-Deichert G, Redaelli M, Büscher G, Graf C, Möhlendick K, Mai J, Gerber A, Lüngen M, Lauterbach KW. 
Int J Public Health. 2008;53(2):78-86. doi: 10.1007/s00038-008-7026-0. PMID: 18681336 Clinical Trial. 

Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance. 
Stock SA, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW. J 
Womens Health (Larchmt). 2008 Apr;17(3):343-54. doi: 10.1089/jwh.2007.0422. PMID: 18338965 

Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma. 
Ramoner R, Rahm A, Gander H, Stollenwerk B, Falkensammer C, Leonhartsberger N, Thurnher M. 
Cancer Immunol Immunother. 2008 Aug;57(8):1207-14. doi: 10.1007/s00262-008-0454-0. Epub 2008 Mar 6. PMID: 18322685

Waiting times for elective treatments according to insurance status: A randomized empirical study in Germany. 
Lungen M, Stollenwerk B, Messner P, Lauterbach KW, Gerber A. 
Int J Equity Health. 2008 Jan 9;7:1. doi: 10.1186/1475-9276-7-1. PMID: 18184426 Free PMC article. 

[Cost-effectiveness of prevention of coronary disease in Germany]. 
Lauterbach KW, Gerber A, Klever-Deichert G, Stollenwerk B. 
Z Kardiol. 2005;94 Suppl 3:III/100-4. doi: 10.1007/s00392-005-1314-y. PMID: 16258785 German.